Sign up to save your podcasts
Or
Share Semaglutide and BP, HF Risk Assessment Using Biomarkers, DAPT After Drug-Eluting Stenting in ACS
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Semaglutide and BP, HF Risk Assessment Using Biomarkers, DAPT After Drug-Eluting Stenting in ACS
In this week’s View, Dr. Eagle looks at an individual patient data meta-analysis of semaglutide and blood pressure (BP). He then explores an analysis from COMBINE-AF on heart failure (HF) risk assessment using biomarkers in patients with atrial fibrillation. Finally, Dr. Eagle discusses short-term dual antiplatelet therapy (DAPT) after drug-eluting stenting in patients with acute coronary syndrome (ACS).
Subscribe to Eagle’s Eye View
View all episodes
By American College of Cardiology
4.7
128128 ratings
In this week’s View, Dr. Eagle looks at an individual patient data meta-analysis of semaglutide and blood pressure (BP). He then explores an analysis from COMBINE-AF on heart failure (HF) risk assessment using biomarkers in patients with atrial fibrillation. Finally, Dr. Eagle discusses short-term dual antiplatelet therapy (DAPT) after drug-eluting stenting in patients with acute coronary syndrome (ACS).
Subscribe to Eagle’s Eye View
More shows like Eagle's Eye View: Your Weekly CV Update From ACC.org
View all
JAMA Editors' Summary
135 Listeners
NEJM This Week
322 Listeners
JACC This Week
169 Listeners
This Week in Cardiology
871 Listeners
JAMA Clinical Reviews
502 Listeners
Circulation on the Run
31 Listeners
Mayo Clinic Talks
281 Listeners
The Curbsiders Internal Medicine Podcast
3,328 Listeners
Core IM | Internal Medicine Podcast
1,111 Listeners
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
60 Listeners
ACC CardiaCast
38 Listeners
Annals On Call Podcast
195 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
348 Listeners
Cardionerds: A Cardiology Podcast
424 Listeners
Mayo Clinic Cardiovascular CME
38 Listeners